Zobrazeno 1 - 6
of 6
pro vyhledávání: '"S. Bill Kangarloo"'
Publikováno v:
Cancer Chemotherapy and Pharmacology
Purpose Tamoxifen is a key therapeutic option for breast cancer treatment. Understanding its complex metabolism and pharmacokinetics is important for dose optimization. We examined the possibility of utilizing archival formalin-fixed paraffin-embedde
Autor:
Georg Hempel, Joachim Boos, S. Bill Kangarloo, James A. Russell, Jeannine S. McCune, Christian Diestelhorst
Publikováno v:
Cancer Chemotherapy and Pharmacology. 72:991-1000
A physiologically based pharmacokinetic (PBPK) model was established and evaluated describing the pharmacokinetics (PK) of the DNA-alkylating agent Busulfan in adults in order to predict the systemic Busulfan drug exposure in both plasma and toxicity
Publikováno v:
Journal of Chromatography B. 931:103-110
An improved quantitative assay was developed and validated for fludarabine in human plasma. Fludarabine and its internal standard, cladribine, were separated on a C18 analytical column after sample purification by strong anion-exchange solid-phase ex
Autor:
Christian Diestelhorst, S. Bill Kangarloo, James A. Russell, Joachim Boos, Jeannine S. McCune, Georg Hempel
Publikováno v:
Pediatric hematology and oncology. 31(8)
A physiologically based pharmacokinetic (PBPK) model of the DNA-alkylating agent busulfan was slightly modified and scaled from adults to children in order to predict the systemic busulfan drug exposure in children. Capitalizing on the recent major s
Autor:
Farrukh Naveed, Douglas A. Stewart, M. Ahsan Chaudhry, Chris M. Brown, M. Lynn Savoie, S. Bill Kangarloo, Nizar J. Bahlis, James A. Russell, Michelle Geddes, Jan Storek, Borje S. Andersson, Diana Quinlan
Publikováno v:
Biology of Blood and Marrow Transplantation. (2):220-228
Low plasma busulfan (Bu) area under the concentration-time curve (AUC) is associated with graft failure and relapsed leukemias, and high AUC with toxicities when Bu is used orally or i.v. 4 times daily combined with cyclophosphamide in myeloablative
Autor:
S. Bill Kangarloo, Nizar J. Bahlis, James A. Russell, Ping Yue, Christopher Brown, Ella S.M. Ng, Nancy Zacarias, Michelle Geddes, Mona Shafey, Peter Duggan, Anthony M. Magliocco, Diana Quinlan, Judy Wu, Andrew Daly, Farrukh Naveed, Douglas A. Stewart, M. Ahsan Chaudhry, Maggie Yang, Mary Lynn Savoie, Jan Storek
Publikováno v:
Biology of Blood and Marrow Transplantation. (2):295-301
Intravenous (i.v.) busulfan (Bu) administered once daily in myeloablative transplant regimens is convenient, effective, and relatively well tolerated. Therapeutic drug monitoring is recommended as nonrelapse mortality increases when daily exposure, a